Breaks Categories: News

TuesdayNov 08, 2022 12:58 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that study program DIAB-A22-1 is expected to begin on schedule today. According to the announcement, this is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes. The company has evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies. Strong connections exist between heart disease, hypertension and diabetes, with hypertension twice as frequent in diabetics and hypertensive patients at greater risk of developing diabetes. Diabetes, which prevents the body from making enough insulin and results in…

Continue Reading

TuesdayNov 01, 2022 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

Continue Reading

ThursdayOct 27, 2022 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol ("CBD") therapy. The study is evaluating Lexaria's patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well…

Continue Reading

WednesdayOct 26, 2022 11:22 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is Oct. 25-31, 2022. “In severe cases of epidermolysis bullosa, or EB, the very fragile skin tears easily and forms painful blisters and open wounds that do not heal quickly,” said Alexandra Mancini, SVP of Clinical and Regulatory Affairs for InMed. “EB is a very important but rare disease that does not get the attention it deserves. EB Awareness…

Continue Reading

TuesdaySep 27, 2022 3:37 pm

CannabisNewsBreaks – The Alkaline Water Company Inc.’s (NASDAQ: WTER) (CSE: WTER) Alkaline88(R) Available in Costco Business Centers

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company, has entered an agreement for its Alkaline88 one-gallon 4-pack to be sold in 15 Costco Business Centers around the country. One of the largest retailers in the world, Costco has more than 110 million members and operates 575 warehouses in the United States and Puerto Rico; its Costco Business Centers focus on serving small business and other enterprises, although all members can shop at the locations. “Costco members shopping at 15 select business centers around the U.S. will now be able to purchase Alkaline88 by the case,”…

Continue Reading

FridaySep 23, 2022 2:41 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. “In the final quarter of our fiscal 2022, as well as throughout the previous fiscal year, we have made important advancements in our pharmaceutical drug development programs, including expanding our phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa to include adolescents, and initiating a research collaboration agreement to further screen cannabinoid analogs for potential therapeutic uses. As announced on Sept. 8, 2022, we have…

Continue Reading

TuesdaySep 20, 2022 2:29 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is focused on establishing a stronghold in the $28 billion hypertension drug market. The company’s exclusive therapeutic, DehydraTECH-CBD, has shown exciting potential as an alternative to traditional cannabidiol (“CBD”) dosing methods; the proprietary treatment may offer improved and more rapid absorption of drugs into the bloodstream and brain. According to the announcement, only one FDA-approved CBD drug is currently available on the market; that drug is for pediatric epilepsy. Lexaria is working to offer the second-ever, FDA-approved CBD therapeutic, designed to treat hypertension. The market for the treatment is tremendous,…

Continue Reading

TuesdaySep 20, 2022 10:46 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it will release the financial report, along with business highlights, on Sept. 23, 2022. In addition, the company has announced a conference call and webcast to be held the same day at 1 p.m. ET. Those interested in listening in on the conference call can register for the call; they will then receive information about how to dial in to the…

Continue Reading

WednesdaySep 14, 2022 10:52 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has closed on a private placement agreement with two healthcare-focused institutional investors. The agreement consisted of the issue and sale of 691,245 of INM common shares prices at $8.68 per share (or prefunded warrant in lieu thereof), totaling approximately $6 million. According to the announcement, INM also issued unregistered preferred investment options allowing the investors to purchase up to 1,382,490 additional common shares. The company observed that the unregistered investment options issued are exercisable upon issuance at an exercise price of $8.44 per share with an…

Continue Reading

TuesdaySep 13, 2022 12:42 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Recognized for Strategic M&A Objectives at Benzinga Cannabis Capital Conference

Flora (NASDAQ: FLGC) is a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands. The company today announced its receipt of the Best M&A Deal award at Benzinga’s 2022 Cannabis Capital Conference in Chicago. “We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers,” said Luis Merchan, chairman and CEO of Flora. To view the full press release, visit https://cnw.fm/vKY3n About Flora Growth Corp. Flora is building a connected, design-led collective of plant-based wellness and lifestyle…

Continue Reading